Hansa Biopharma Investor Presentation — October 2021

Document content

…atHansaBiopharmaweenvisionaworldwhereallpatientswithrareimmunologicdiseasescanleadlongandhealthylives...Investor Road Show Presentation Q3 2021Lund, October 21, 2021Thispresentationmaycontaincertainforward-lookingstatementsandforecastsbasedonourcurrentexpectationsandbeliefsregardingfutureeventsandaresubjecttosignificantuncertaintiesandriskssincetheyrelatetoeventsanddependoncircumstancesthatwilloccurinthefuture.Someoftheseforward-lookingstatements,bytheirnature,couldhaveanimpactonHansaBiopharma’sbusiness,financialconditionandresultsofoperations[orthatofitsparent,affiliate,orsubsidiarycompanies].Termssuchas“anticipates”,“assumes”,“believes”,“can”,“could”,“estimates”,“expects”,“forecasts”,“intends”,“may”,“might”,“plans”,“should”,“projects”,“will”,“would”or,ineachcase,theirnegative,orothervariationsorcomparableterminologyareusedtoidentifyforward-lookingstatements.Thereareanumberoffactorsthatcouldcauseactualresultsanddevelopmentstodiffermateriallyfromthoseprojected,whetherexpresslyorimpliedly,inaforward-lookingstatementoraffecttheextenttowhichaparticularprojectionisrealized.Suchfactorsmayinclude,butarenotlimitedto,changesinimplementationofHansaBiopharma’sstrategyanditsabilitytofurthergrow;risksanduncertaintiesassociatedwiththedevelopmentand/orapprovalofHansaBiopharma’sproductcandidates;ongoingclinicaltrialsandexpectedtrialresults;theabilitytocommercializeimlifidaseifapproved;changesinlegalorregulatoryframeworks,requirements,orstandards;technologychangesandnewproductsinHansaBiopharma’spotentialmarketandindustry;theabilitytodevelopnewproductsandenhanceexistingproducts;theimpactofcompetition,changesingeneraleconomyandindustryconditionsandlegislative,regulatoryandpoliticalfactors.Thefactorssetforthabovearenotexhaustiveandadditionalfactorscouldadverselyaffectourbusinessandfinancialperformance.Weoperateinaverycompetitiveandrapidlychangingenvironment,anditisnotpossibletopredictallfactors,norcanweassesstheimpactofallfactorsonourbusinessortheextenttowhichanyfactor,orcombinationoffactors,maycauseactualresultstodiffermateriallyfromthosecontainedinanyforward-lookingstatements.Giventheserisksanduncertainties,investorsshouldnotplaceunduerelianceonforward-lookingstatementsasapredictionofactualresults.HansaBiopharmaexpresslydisclaimsanyobligationtoupdateorreviseanyforward-lookingstatementstoreflectchangesinunderlyingassumptionsorfactors,newinformation,futureeventsorotherwise,anddisclaimsanyexpressorimpliedrepresentationsorwarrantiesthatmayarisefromanyforward-lookingstatements.Youshouldnotrelyupontheseforward-lookingstatementsafterthedateofthispresentation.

2Forward-looking statementsTable of contents1.Q3 2021 Business Update………………..2.Company overview………………………..3.Imlifidasein kidney transplantations….…..4.Completed and ongoing studies…………. 5.Our enzyme technology………….……….6.Clinical development programs……….....7.Pre-clinical programs……………………..8.Gene therapy…………………….………..9.ESG Overview………………………….....10.Capital Markets…………………………...